



# **Future Role of Echocardiography in the Era of Multimodality Imaging**

**Yong-Jin Kim, MD**

**Seoul National University Hospital**

# Multimodality Cardiac Imaging



**If you are left on a desert island....**

**What do you want to have for your patients?**



# Strength and Current Role of Echo

- **Hemodynamic evaluation**
  - **Diagnosis and therapeutic guidance for valve stenosis, HF, HFNEF, and more...**





# Hemodynamic Evaluation

## Valve Stenosis

### Aortic Stenosis


### Mitral Stenosis




# Guidelines for Valve Stenosis

## Severe Aortic Stenosis

$V_{max}$  greater than 4 m/s  
 AVA less than  $1.0 \text{ cm}^2$   
 Mean gradient  $> 40 \text{ mm Hg}$



## Mitral Stenosis



# **Hemodynamic Evaluation**


## ***Noninvasive Swan-Ganz Catheter***

**Editorial**

**Echocardiography as a Noninvasive Swan-Ganz Catheter**

Jae K. Oh, MD


# Sudden Dyspnea in pt with Cardiomyopathy



**What is the most important information for you?**

# Hemodynamic Evaluation



## *LV Filling Pressure*







# Case 1: 65 yo gentleman

*known COPD: ER due to dyspnea*



# Case 1: 2 months later





# How to diagnose HFNEF

Symptoms or signs of heart failure

Normal or mildly reduced left ventricular systolic function  
LVEF > 50%  
and  
LVEDVI < 97 mL/m<sup>2</sup>

Evidence of abnormal LV relaxation, filling, diastolic distensibility, and diastolic stiffness

Invasive Haemodynamic measurements  
mPCW > 12 mmHg  
or  
LVEDP > 16 mmHg  
or  
 $\tau$  > 48 ms  
or  
 $b$  > 0.27

TD  
 $E/E' > 15$      $15 > E/E' > 8$


Biomarkers  
NT-proBNP > 220 pg/ml  
or  
BNP > 200 pg/mL

Biomarkers  
NT-proBNP > 220 pg/mL  
or  
BNP > 200 pg/mL


Echo – bloodflow Doppler  
 $E/A_{>50 \text{ yr}} < 0.5$  and  $DT_{>50 \text{ yr}} > 280 \text{ ms}$   
or  
 $Ard-Ad > 30 \text{ ms}$   
or  
 $LAVI > 40 \text{ mL/m}^2$   
or  
 $LVMI > 122 \text{ g/m}^2$  (♀);  $> 149 \text{ g/m}^2$  (♂)  
or  
Atrial fibrillation

TD  
 $E/E' > 8$

# Case 2. Aggravated Dyspnea in pt with Endocarditis




# Acute AR Hemodynamics





# Acute AR Hemodynamics





# Strength and Current Role of Echo

- **Hemodynamic evaluation**
  - Valve stenosis, HF
- **Portability**
  - The best imaging modality for critical pts

## Case 3: 55 yo woman

### *Sudden Collapse at Psychiatric Ward*




# Strength and Current Role of Echo

- Hemodynamic evaluation
  - Valve stenosis, HF
- Portability
  - The best imaging modality for critical pts
- Versatility
  - intraOp TEE, intracardiac,
  - Therapeutic echo: ASD closure, pericardiocentesis, PMV, biopsy, alcohol ablation



# Case 5: BP Drop after Induction for CABG

*Under intensive inotropics*




# SAM during coronary bypass Op

*Intensive  
inotropics*




*Stop inotropics  
Hydration*




# Echo for ASD Device Closure

## Transesophageal






## Intracardiac





# Echo for TAVI





Courtesy of Prof. SJ Park



# **Strength and Current Role of Echo**

- **Hemodynamic evaluation**
  - **Valve stenosis, HF**
- **Portability**
  - **The best imaging modality for critical pts**
- **Versatility**
  - **IntraOp TEE, ICE, Therapeutic echo**
- **High temporal, spatial resolution**
  - **Detection of intracardiac mass**

# Case: Endocarditis




# LV Mass





# LV Papillary Fibroelastoma



# Strength and Current Role of Echo

- **Hemodynamic evaluation**
  - Valve stenosis, HF
- **Portability**
  - The best imaging modality for critical pts
- **Versatility**
  - IntraOp TEE, ICE, Therapeutic echo
- **High temporal, spatial resolution**
  - Detection of intracardiac mass
- **Exercise physiology: CAD, Valve ds, Diastolic stress**

# Exercise Echo




Courtesy of Prof. WS Kim



Courtesy of Prof. JW Ha

# Exercise Echo for CAD






# Exercise Echo in MR

*latent LV dysfunction*



139 pt with chronic MR



Leung et al, JACC 1996

# Exercise Echo in MR

## *Source of symptoms*




LVEDD = 53mm

LVESD = 27mm

EF = 74 %

# Exercise Echo in MR

## Source of symptoms





PA systolic pr = 34mmHg


PA systolic pr = 64mmHg



# Exercise Echo in MS

## Determinants of exercise capacity






# Strength and Current Role of Echo


- **Hemodynamic evaluation: Valve stenosis, HF**
- **Portability: The best imaging modality for critical pts**
- **Versatility: IntraOp TEE, ICE, Therapeutic echo**
- **High temporal, spatial resolution**
  - **Detection of intracardiac mass**
- **Exercise physiology: CAD, Valve ds, Diastolic stress**
- **Lower cost**
  - **Regular F/U, screening, developing country**

# Average Costs






# Epidemics of Imaging




**Figure 1.** MedPAC Evaluation of Growth in Physician Services From 1999 to 2000

# Cancer Risk and Radiation




# Echo Screening for Rheumatic Valve



Marijon E, et al. NEJM 2007


# Weakness and Recent Development

- Poor image quality
  - Contrast echocardiography







# LV Opacification with Contrast Echo




Courtesy of Prof. GR Hong

# Apical HCM: Pitfalls in Diagnosis



# Apical Thrombus



Courtesy of Prof. GR Hong

# Weakness and Recent Development

- **Poor image quality**
  - **Contrast echocardiography**
- **Large variability**
  - **Automation**




# Interpretation of Stress Echo

1994


2000

Number of studies Kappa=0.37




Number of studies

Kappa=0.55




# Regional Myocardial Function

## 2D Speckle Strain



# Automated Volume Measurement




# Weakness and Recent Development


- **Poor image quality**
  - **Contrast echocardiography**
- **Large variability**
  - **Automation**
- **Geometric assumption**
  - **Real-time 3D echo**



# 3D Echo




# LV Volume (RT3DE vs. MRI)




*Kuhl, JACC 2004;43:2083-90*

# 3D LV Opacification



Courtesy of Prof. JH Choi

# LV Opacification with 3D Echo




Courtesy of Prof. JH Choi

# Weakness and Recent Development

- **Poor image quality**
  - **Contrast echocardiography**
- **Large variability**
  - **Automation**
- **Geometric assumption**
  - **Real-time 3D echo**
- **Miniaturization: “point-of-care echo”**




# Miniaturization



# Weakness and Recent Development



- **Poor image quality**
  - **Contrast echocardiography**
- **Large variability**
  - **Automation**
- **Geometric assumption**
  - **Real-time 3D echo**
- **Miniaturization: “point-of-care echo”**
- **Rapid development of 3D echo**

# MV Prolapse




Courtesy of Prof. JM Song

# MV Prolapse on 3D TEE



**Figure 1.** Overall accuracy of the 4 techniques in the identification of mitral valve pathology. \* $p < 0.001$  versus 2D TTE; † $p < 0.001$  versus 3D TTE; § $p < 0.001$  versus 2D TEE. 2D = two-dimensional; 3D = three-dimensional; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography.

# 3D Strain Imaging





# Future Role of Echo in the Era of Multimodality Imaging

*Which One Do You Prefer?*

Life without  
Echo

Life without  
Cardiac CT

Life without  
Cardiac MR

# **Our Responsibility as a Echo Specialist**

- **Education for the quality assurance**
  - **Relatively easy, availability**
- **Communication with surgeons & interventionist**
- **Knowledge & experience with other imaging modalities**
- **Cost-effectiveness**
- **Outcome trials**

# STICH Trial

*The NEW ENGLAND JOURNAL of MEDICINE*


ORIGINAL ARTICLE

## Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction

Robert O. Bonow, M.D., Gerald Maurer, M.D., Kerry L. Lee, Ph.D., Thomas A. Holly, M.D., Philip F. Binkley, M.D., Patrice Desvigne-Nickens, M.D., Jaroslaw Drozd, M.D., Ph.D., Pedro S. Farsky, M.D., Arthur M. Feldman, M.D., Torsten Doenst, M.D., Ph.D., Robert E. Michler, M.D., Daniel S. Berman, M.D., Jose C. Nicolau, M.D., Ph.D., Patricia A. Pellikka, M.D., Krzysztof Wrobel, M.D., Nasri Alotti, M.D., Ph.D., Federico M. Asch, M.D., Liliana E. Favalaro, M.D., Lilin She, Ph.D., Eric J. Velazquez, M.D., Robert H. Jones, M.D., and Julio A. Panza, M.D., for the STICH Trial Investigators\*

# Is Viability Test "Viable"?


**A Without Myocardial Viability**



**No. at Risk**

Medical therapy	60	51	44	39	29	14	4
CABG	54	48	41	41	34	22	12


**B With Myocardial Viability**



**No. at Risk**

Medical therapy	243	219	206	179	146	94	51
CABG	244	213	203	192	148	94	51

**C**



**Thank You for Your Attention!**



**T H A N K Y O U**